The recent ICH Q9: Quality Risk Management revision includes new guidance on facilitating a risk-based decision-making approach using science and knowledge.

Warning Letters FY2020 and FY2021

Kevin O’Donnell, PhD, Market Compliance Manager, Irish Health Products Regulatory Authority (HPRA) provided an update on the ICH Q9 revision at the 2021 PDA/FDA Joint Regulatory Conference last fall, ahead of the December 2021 release of the revision.  

ICH Q9 originally was  finalized in 2005, “and as we all know, QRM (quality risk management) has  become very important in our industry…we have had many initiatives to embed risk management principles and risk-based approaches into our day-to-day work and into our strategic goals as well.”

O’Donnell’s agency proposed a revision to ICH Q9 in 2018, and he worked with two colleagues, Gregg Claycamp, Senior Scientist for Risk Analysis and Decision Analysis, U.S. FDA, and Emma Ramnarine, Senior Director, Global Head External Development Collaborations, Genentech/Roche, to prepare the initial proposal paper. 

In November 2019, ICH accepted the proposal to revise ICH Q9 and established an Expert Working Group in 2020.

“We have been working since then to come up with good and new guidance on QRM,” he said.

O’Donnell anticipates that the guidance will be finalized in September 2022, although the business plan states May 2022.

[Author’s Note: EMA published the draft revision on the agency’s website in December. Comments will be accepted by EMA until March 15. As the document is at Step 2 of the ICH process, the ICH Q9 revision has been sent to regulatory bodies within ICH regions for internal and external comments per the procedures of those agencies. For this reason, the document is not on the ICH website.]

In his PDA/FDA presentation, he further clarified this is only a targeted revision and not a full rewrite, as most of the existing guidance remains unchanged.

The revision focuses on six specific topics:

  • Subjectivity in QRM
  • Product availability risks
  • Formality in QRM
  • Risk-based decision-making
  • Risk review
  • Hazard identification

Subjectivity in QRM

Regarding subjectivity, “this is a pretty important part of understanding, assessing, and making decisions regarding risk, but it is quite a tricky area to get right, and it is quite a tricky area to write guidance on. High levels of subjectivity in risk assessments and QRM outputs is problematic.”

Subjectivity also is not in line with the first ICH Q9 principle: Risks to quality should be evaluated based on scientific knowledge.

“We know we cannot eliminate subjectivity from QRM, but we know we can control it, and there is a lot of peer-reviewed research out there from other industries telling us how one can control subjectivity using various strategies, which address bias and various behavioral factors, groupthink, group work, etc.,” O’Donnell explained. “We think addressing subjectivity will be beneficial because less subjective risk assessments should lead to more scientific control strategies, validation protocols, and, hopefully, fewer quality defects because processes will have better risk-based validation behind them.”

He added, “these improvements also, hopefully, will continue to support the implementation of ICH Q8, Q10, Q11, and Q12—all of which expect scientific approaches.”

[Author’s Note: For more on ICH Q10: Pharmaceutical Quality System, watch the following video clip featuring consultant Fenton Fong.]

Product Availability Risks

This type of risk can also be read as “drug shortage risks,” according to the HPRA regulator. 

“We know ICH Q9 is not a supply chain guidance, but quality and manufacturing issues that impact product availability do present risks to patients, so managing those risks is important,” he said. “We think addressing these risks across the lifecycle is very important given the globalization of medicine supply chains.”

The goal of the ICH Q9 revision in this area is for companies to develop risk-based drug shortage prevention and mitigation plans.

Formality in QRM

“Formality is an interesting topic in QRM,” O’Donnell said. “ICH Q9 currently states that the level of effort, formality, and documentation of the QRM process should be commensurate with the level of risk.”

There is a level of ambiguity regarding formality, however, and many stakeholders have told O’Donnell and his colleagues they do not understand what formality in QRM really means, resulting in confusion. Regulators are also uncertain about what “formality” means. 

The revision covers degrees of formality and approaches formality as a spectrum rather than a binary approach.

“We are going to be discussing the factors that might influence how much formality might be applied,” he said.

We know we cannot eliminate subjectivity from QRM, but we know we can control it

O’Donnell emphasized that flexibility is critical in determining how much formality to apply to QRM.

“Clarity here will help ensure that the extent of scientific rigor and the methodological rigor applied during QRM work is commensurate with risk levels,” he said. “We will have resources being used more efficiently in the future, where lower risk issues are dealt with more efficiently via less formal means, to free up resources for managing higher-risk issues and more complex problems.”

Risk-Based Decision-Making

Per O’Donnell, risk-based decision-making is a large topic as it “ultimately translates back to risk-based decision making…while ICH Q9 does make reference to this concept, there is currently some lack of clarity on what good risk-based decision making actually is, how it might be achieved, and how QRM may improve decision making generally.”

He noted that other sectors have conducted research about risk-based decision making, including nuclear power, aeronautics, the U.S. Coast Guard, and others.

“The revision work will hopefully provide clarity here, and address the expected benefits of investing in risk-based decision-making process activities,” he said. “Hopefully, this will all lead to lots of good things: better risk assessments, better control strategies in our manufacturing process, and more access to new medicines for patients, especially when we are looking at fast-tracked applications.”

Risk Review

The fifth topic, risk review, is a smaller topic within the overall revision. The revision does not include any new guidance on the topic because the team felt that the current guidance is sufficient. However, training materials addressing risk reviews will be included.

There is a level of ambiguity regarding formality

“The training materials we will generate will provide additional clarity on expectations relating to risk reviews and keeping risk assessment current, and linking that with continual improvement,” O’Donnell explained. “We will be looking at lifecycle types of examples to illustrate when it [risk review] is done well what it might look like, tying in with the concept of continuous improvement.”

Hazard Identification

ICH Q9 right now uses the term risk identification, “but we are going to revise the guideline to change that phrase to the phrase, ‘hazard identification,’ because this will better reflect what is already in ICH Q9, which does speak about how risk assessment consists of the identification of hazards, and the analysis and evaluation of their risks and the exposure to those hazards. We want to address that particular discrepancy right now.”

O’Donnell said his team thinks that this update will help with identifying patient hazards when evaluating risks, culminating in improvements in the classification of hazards, perceptions, assessments, etc.

ICH Q9 Revision Addresses New Tech

The GMP inspector’s experience with recent quality defects illustrates the importance of this revision, notably, the issue with nitrosamine contamination. 

“A revised Q9 could lead to more effective and science-based control strategies, improving consistency in manufacturing, and lowering costs, he said. “There is nothing wrong with mentioning lowering costs and reducing the likelihood of defects, recalls, and medicine shortages. We will also be trying to speak about the emergence and the use of new technologies and innovation and how the use of QRM is still very important when new technologies and innovation are being brought into manufacturing.”

As manufacturers adopt big data, automation, including robotics, O’Donnell views the ICH Q9 revision as critical.

“The use of QRM will become increasingly important when one is trying, for example, to validate those applications and those new ways of working, and things like robotics, automation, and data analytics which are based on advanced technologies,” he said.

Ultimately, O’Donnell and his colleagues who worked on the revision would like to see more risk-based oversight. 

“We are getting there, but we are going to get there more quickly, hopefully, with this revision of ICH Q9.”

Additional Resources

Taking a Risk-Based Approach to QMS

What is Risk-Based Thinking?

FDA: How Pharma Companies Are Unknowingly Introducing Risk Into Their Quality Management Systems

Find out how Redica Systems can provide you with actionable intelligence to identity enforcement trends concerning QRM areas of focus. Schedule a tour of our platform today!

Redica Systems tour

Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Webinar: Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Presented by Jerry Chapman on October 29, 2020

What you will learn:

  • A comparison of 483 observations in FY2019
  • Top 10 Russian Ministry of Health inspection findings
  • Top 10 FDA Warning Letter findings
  • Top MHRA inspection findings
Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Champion of Change - 3Cs to Success

Webinar: Champion of Change - 3Cs to Success

Presented by Steve Greer on June 23, 2020

What you will learn:

  • The 3C Model to become a champion of change
  • How to identify game-changing habits and the steps to implement them
  • Ways to develop greater purpose-centered leadership
  • How to generate awareness along with actions to create changes in how you think about challenges and change putting you on a path to lead change successfully in your organization
  •  

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity
Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.